<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="620">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000484640</actrnumber>
  <trial_identification>
    <studytitle>Efficacy study of Faulding's sea cucumer extracts in osteoarthritis.</studytitle>
    <scientifictitle>Randomised, double-blind, three armed, placebo controlled trial comparing the safety and efficacy of sea cucumber extract, sea cucumber extract with Boswellia extract and placebo in adults with osteoarthritis.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cucumaria frondosa extract 1000mg or Cucumaria frondosa extract 1000mg plus 400mg Boswellia serrata extract over 11 weeks.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in clinical symptoms of osteoarthritis as measured by the WOMAC osteoarthritis index after 11 weeks treatment</outcome>
      <timepoint>After 11 weeks treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1) Change in clinical symptoms of osteoarthritis as measured by the Comprehensive Osteoarthritis Test (COAT).</outcome>
      <timepoint>After 11 weeks treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2) Changes in platelet aggregation, euglobulin clot lysis times, lipid profiles and YKL-40.</outcome>
      <timepoint>After 11 weeks treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Diagnosis of OA of the hip or knee. 2) Willing to discontinue all current OA treatment for the study duration commencing 4 weeks prior to baseline.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Severe false alignment of the knee or hip2) Surgery or arthroscopy of the knee or hip within 2 months of baseline3) Infectious or inflammatory rheumatic disease4) Reliance on the use of lipolytic, fibrinolytic, anti-coagulant or anti-inflammatory agents5) A history of trauma associated with the affected joints6) Any condition that in the opinion of the investigator might interfere with the evaluation of the study objective.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Study medications were supplied in numbered containers by the sponsor</concealment>
    <sequence>Computer generated block randomisation scheme</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>5/06/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>129</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Faulding Healthcare Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Faulding Healthcare Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Mater Health Services 
Level 2
Community Services Building
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax>+61 7 38406119</fax>
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Mater Health Services 
Level 2
Community Services Building
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax>+61 7 38406119</fax>
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>